Stephen Bloch Sells 25,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 25,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $80.17, for a total value of $2,004,250.00. Following the sale, the director directly owned 830,073 shares in the company, valued at approximately $66,546,952.41. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Stock Performance

NASDAQ LQDA opened at $81.45 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $13.23 and a twelve month high of $82.96. The business has a 50-day moving average price of $64.20 and a 200-day moving average price of $46.68. The firm has a market cap of $7.24 billion, a price-to-earnings ratio of 581.83 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue for the quarter was up 4187.1% compared to the same quarter last year. As a group, equities research analysts predict that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Oppenheimer set a $75.00 target price on shares of Liquidia in a research report on Friday, June 5th. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Wells Fargo & Company increased their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $68.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia in the fourth quarter valued at about $25,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia in the second quarter worth $25,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the 3rd quarter worth $34,000. Covestor Ltd raised its stake in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after acquiring an additional 4,927 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).